Lelli G - Search Results

1

A new regimen of cisplatin, epirubicin and methotrexate (PEM-3) as primary chemotherapy for locally advanced bladder cancer.

Cacciari N, Martoni A, Rossi AP, Turci P, Lelli G, Martinelli A, Maver P, Corrado F, Mannini D, Reggiani A, Concetti S, Martelli A, Melotti B, Cricca A, Zamagni C, Pannuti F. Cacciari N, et al. Among authors: lelli g. Tumori. 1996 Jul-Aug;82(4):364-8. doi: 10.1177/030089169608200413. Tumori. 1996. PMID: 8890971 Clinical Trial.

2

Cisplatinum plus epirubicin alternated with cyclophosphamide plus 5-fluorouracil in ovarian cancer.

Martoni A, Ercolino L, Bellucco A, Canova N, Lelli G, Pannuti F. Martoni A, et al. Among authors: lelli g. J Chemother. 1990 Feb;2(1):62-6. doi: 10.1080/1120009x.1990.11738983. J Chemother. 1990. PMID: 2332785

3

Low dose intermittent 5-fluorouracil, epirubicin and cyclophosphamide (FEC) in poor risk patients with advanced transitional cell bladder cancer: a pilot study.

Lelli G, Tononi A, Bacchetti P, Maver P, Corrado G, Garofalo F, De Santis P, Pannuti F. Lelli G, et al. J Chemother. 1989 Aug;1(4):269-71. doi: 10.1080/1120009x.1989.11738906. J Chemother. 1989. PMID: 2809695

4

Dose intensification of chemotherapy in advanced breast cancer: a feasibility phase II study.

Pedrazzoli P, Zamagni C, Martoni A, Capotorto AM, Da Prada GA, Pavesi L, Preti P, Lelli G, Pannuti F, Robustelli della Cuna G. Pedrazzoli P, et al. Among authors: lelli g. Tumori. 1994 Aug 31;80(4):273-5. doi: 10.1177/030089169408000405. Tumori. 1994. PMID: 7526508 Clinical Trial.

5

Chemotherapy with cisplatin, epirubicin, methotrexate in the treatment of locally advanced or metastatic transitional cell cancer of the bladder (TCC).

Lelli G, Melotti B, Pannuti F, Rossi AP, Maver P, Mannini D, Corrado G, Severini G, Bercovich E, Beghelli R, et al. Lelli G, et al. J Chemother. 1992 Aug;4(4):239-43. doi: 10.1080/1120009x.1992.11739172. J Chemother. 1992. PMID: 1403081 Clinical Trial.

6

The antiemetic efficacy and the cost-benefit ratio of ondansetron calculated with a new approach to health technology assessment (real cost-benefit index).

Tanneberger S, Lelli G, Martoni A, Piana E, Pannuti F. Tanneberger S, et al. Among authors: lelli g. J Chemother. 1992 Oct;4(5):326-31. doi: 10.1080/1120009x.1992.11739186. J Chemother. 1992. PMID: 1479424 Clinical Trial.

7

A phase II study on lonidamine combined with cisplatin and etoposide in the treatment of advanced non-small cell bronchogenic carcinoma (NSCBC).

Lelli G, Guaraldi M, Canova N, Casadio M, Pannuti F. Lelli G, et al. J Chemother. 1990 Dec;2(6):401-4. doi: 10.1080/1120009x.1990.11739053. J Chemother. 1990. PMID: 1965508

8

Small cell bronchogenic carcinoma: a cyclical alternating combination of epirubicin plus cisplatin and cyclophosphamide plus etoposide.

Casadio M, Lelli G, Giordani S, Boltri B, Blotta A, Busutti L, Ramini R, Falcone F, Pannuti F. Casadio M, et al. Among authors: lelli g. J Chemother. 1990 Jun;2(3):199-202. doi: 10.1080/1120009x.1990.11739018. J Chemother. 1990. PMID: 2166145

9

A phase III study on intermittent versus weekly cisplatin and etoposide in the treatment of advanced non-small cell bronchogenic carcinoma.

Lelli G, Casadio M, Farris A, Tononi A, Giordani S, Pannuti F. Lelli G, et al. J Chemother. 1989 Apr;1(2):136-9. doi: 10.1080/1120009x.1989.11738880. J Chemother. 1989. PMID: 2659747 Clinical Trial.

10

Combined chemo-immuno-hormonotherapy of advanced renal cell carcinoma.

Panetta A, Martoni A, Guaraldi M, Tamberi S, Casadio M, Lelli G, Pannuti F. Panetta A, et al. Among authors: lelli g. J Chemother. 1994 Oct;6(5):349-53. doi: 10.1080/1120009x.1994.11741171. J Chemother. 1994. PMID: 7861200

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

152 results

Search Page

Filters